{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:49Z","timestamp":1787027809472,"version":"build-2736575974"},"reference-count":66,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universit\u00e9 de Montr\u00e9al at H\u00f4pital Maisonneuve-Rosemont"},{"name":"Fonds de recherche du Qu\u00e9bec\u2013Sant\u00e9"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Fluorescence in situ hybridization (FISH) on enriched CD138 plasma cells is the standard method for identification of clinically relevant genetic abnormalities in multiple myeloma. However, FISH is a targeted analysis that can be challenging due to the genetic complexity of myeloma. The aim of this study was to evaluate the potential of optical genome mapping (OGM) to detect clinically significant cytogenetic abnormalities in myeloma and to provide larger pangenomic information. OGM and FISH analyses were performed on CD138-purified cells of 20 myeloma patients. OGM successfully detected structural variants (SVs) (IGH and MYC rearrangements), copy number variants (CNVs) (17p\/TP53 deletion, 1p deletion and 1q gain\/amplification) and aneuploidy (gains of odd-numbered chromosomes, monosomy 13) classically expected with myeloma and led to a 30% increase in prognosis yield at our institution when compared to FISH. Despite challenges in the interpretation of OGM calls for CNV and aneuploidy losses in non-diploid genomes, OGM has the potential to replace FISH as the standard of care analysis in clinical settings and to efficiently change how we identify prognostic and predictive markers for therapies in the future. To our knowledge, this is the first study highlighting the feasibility and clinical utility of OGM in myeloma.<\/jats:p>","DOI":"10.3390\/cancers15194687","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:48:31Z","timestamp":1695552511000},"page":"4687","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma"],"prefix":"10.3390","volume":"15","author":[{"given":"Am\u00e9lie","family":"Gigu\u00e8re","sequence":"first","affiliation":[{"name":"Cytogenetics Laboratory, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7685-5262","authenticated-orcid":false,"given":"Isabelle","family":"Raymond-Bouchard","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Collin","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Claveau","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Universit\u00e9 de Montr\u00e9al, Montreal, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-1353","authenticated-orcid":false,"given":"Jos\u00e9e","family":"H\u00e9bert","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"},{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Universit\u00e9 de Montr\u00e9al, Montreal, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Universit\u00e9 de Montr\u00e9al, Montreal, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cardona-benavides, I.J., de Ram\u00f3n, C., and Guti\u00e9rrez, N.C. (2021). Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells, 10.","DOI":"10.3390\/cells10020336"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy Is a Major Prognostic Factor in Multiple Myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.dnarep.2006.05.012","article-title":"Distinguishing Primary and Secondary Translocations in Multiple Myeloma","volume":"5","author":"Gabrea","year":"2006","journal-title":"DNA Repair"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Luo, S., Su, T., Zhou, X., Hu, W.-X., and Hu, J. (2022). Chromosome 1 Instability in Multiple Myeloma: Aberrant Gene Expression, Pathogenesis, and Potential Therapeutic Target. FASEB J., 36.","DOI":"10.1096\/fj.202200354"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Flynt, E., Bisht, K., Sridharan, V., Ortiz, M., Towfic, F., and Thakurta, A. (2020). Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9020287"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of Genomic Evolution and Mutational Profiles in Multiple Myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients with Newly Diagnosed Myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41467-017-00638-w","article-title":"Expressed Fusion Gene Landscape and Its Impact in Multiple Myeloma","volume":"8","author":"Cleynen","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","article-title":"Chromothripsis as a Pathogenic Driver of Multiple Myeloma","volume":"123","author":"Maura","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of Multiple Myeloma with High-Risk Cytogenetics: A Consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-20-2283","article-title":"Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma","volume":"26","author":"Abdallah","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.18243","article-title":"How Do We Manage t(11;14) Plasma Cell Disorders with Venetoclax?","volume":"199","author":"Chakraborty","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-023-00807-9","article-title":"Multiple Myeloma with t(11;14): Impact of Novel Agents on Outcome","volume":"13","author":"Puertas","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group Molecular Classification of Multiple Myeloma: Spotlight Review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.leukres.2015.02.010","article-title":"The Clinical Characteristics and Prognosis of IGH Deletion in Multiple Myeloma","volume":"39","author":"He","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/gcc.22874","article-title":"High-Risk Cytogenetics in Multiple Myeloma: Further Scrutiny of Deletions within the IGH Gene Region Enhances Risk Stratification","volume":"59","author":"Smith","year":"2020","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rabani, H., Ziv, M., Lavi, N., Aviv, A., Suriu, C., Shalata, A., Haddid, Y., and Tadmor, T. (2020). Deletions and Amplifications of the IGH Variable and Constant Regions: A Novel Prognostic Parameter in Patients with Multiple Myeloma. Leuk. Res., 99.","DOI":"10.1016\/j.leukres.2020.106476"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Coccaro, N., Anelli, L., Zagaria, A., Tarantini, F., Cumbo, C., Tota, G., Minervini, C.F., Minervini, A., Conserva, M.R., and Redavid, I. (2023). Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA. Diagnostics, 13.","DOI":"10.3390\/diagnostics13111841"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Valkama, A., Vorimo, S., Kumpula, T.A., R\u00e4s\u00e4nen, H., Savolainen, E.-R., Pylk\u00e4s, K., and Mantere, T. (2023). Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15041294"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"L\u00fchmann, J.L., Stelter, M., Wolter, M., Kater, J., Lentes, J., Bergmann, A.K., Schieck, M., G\u00f6hring, G., M\u00f6ricke, A., and Cario, G. (2021). The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13174388"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Suttorp, J., L\u00fchmann, J.L., Behrens, Y.L., G\u00f6hring, G., Steinemann, D., Reinhardt, D., von Neuhoff, N., and Schneider, M. (2022). Optical Genome Mapping as a Diagnostic Tool in Pediatric Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14092058"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Soler, G., Ouedraogo, Z.G., Goumy, C., Lebecque, B., Aspas Requena, G., Ravinet, A., Kanold, J., V\u00e9ron\u00e8se, L., and Tchirkov, A. (2023). Optical Genome Mapping in Routine Cytogenetic Diagnosis of Acute Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15072131"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/ijc.33942","article-title":"Optical Genome Mapping Reveals Additional Prognostic Information Compared to Conventional Cytogenetics in AML\/MDS Patients","volume":"150","author":"Gerding","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kriegova, E., Fillerova, R., Minarik, J., Savara, J., Manakova, J., Petrackova, A., Dihel, M., Balcarkova, J., Krhovska, P., and Pika, T. (2021). Whole-Genome Optical Mapping of Bone-Marrow Myeloma Cells Reveals Association of Extramedullary Multiple Myeloma with Chromosome 1 Abnormalities. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93835-z"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/TACG.S262866","article-title":"Genetic Predictors of Mortality in Patients with Multiple Myeloma","volume":"14","author":"Hassan","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia Translocations: Molecular-Cytogenetic Characterization and Prognostic Influence on Frontline Imatinib Therapy, a GIMEMA Working Party on CML Analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1989.tb04272.x","article-title":"Chromosome Rearrangement, t(6;14) (P21.1;Q32.3), in Multiple Myeloma","volume":"71","author":"Nishida","year":"1989","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood.V98.9.2837","article-title":"Cyclin D3 Is a Target Gene of t(6;14)(P21.1;Q32.3) of Mature B-Cell Malignancies","volume":"98","author":"Sonoki","year":"2001","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 Is Dysregulated by Recurrent Chromosomal Translocations to Immunoglobulin Loci in Multiple Myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ijlh.12882","article-title":"Recent Advances in Cytogenetic Characterization of Multiple Myeloma","volume":"41","author":"Saxe","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in Multiple Myeloma: Impact on Survival in Patients with High-Risk Cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic Abnormalities and Survival in Multiple Myeloma: The Experience of the Intergroupe Francophone Du My\u00e9lome","volume":"109","author":"Attal","year":"2007","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","article-title":"Ploidy, as Detected by Fluorescence in Situ Hybridization, Defines Different Subgroups in Multiple Myeloma","volume":"19","author":"Wuilleme","year":"2005","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1365-2141.2000.02488.x","article-title":"Chromosome 13 Abnormalities in Multiple Myeloma Are Mostly Monosomy 13","volume":"111","author":"Daviet","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/ejh.13905","article-title":"Amp(1q) and Tetraploidy Are Commonly Acquired Chromosomal Abnormalities in Relapsed Multiple Myeloma","volume":"110","author":"Locher","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1002\/ajh.25420","article-title":"Tetraploidy Is Associated with Poor Prognosis at Diagnosis in Multiple Myeloma","volume":"94","author":"Sidana","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome","volume":"119","author":"Schlenk","year":"2012","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1078-0432.CCR-16-0594","article-title":"Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation","volume":"23","author":"Yu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/leu.2008.143","article-title":"Mutations of the TP53 Gene in Acute Myeloid Leukemia Are Strongly Associated with a Complex Aberrant Karyotype","volume":"22","author":"Haferlach","year":"2008","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The Prognostic Impact of 17p (P53) Deletion in 2272 Adults with Acute Myeloid Leukemia","volume":"23","author":"Seifert","year":"2009","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Pang, A.W.C., Kosco, K., Sahajpal, N., Sridhar, A., Hauenstein, J., Clifford, B., Estabrook, J., Chitsazan, A., Sahoo, T., and Iqbal, A. (2022). Clinical Validation of Optical Genome Mapping for the Detection of Structural Variations in Hematological Malignancies. medRxiv.","DOI":"10.1101\/2022.12.27.22283973"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1182\/bloodadvances.2022007583","article-title":"Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation","volume":"7","author":"Levy","year":"2023","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Puiggros, A., Ramos-Campoy, S., Kamaso, J., de la Rosa, M., Salido, M., Melero, C., Rodr\u00edguez-Rivera, M., Bougeon, S., Collado, R., and Gimeno, E. (2022). Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). Cancers, 14.","DOI":"10.3390\/cancers14143376"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jmoldx.2022.09.009","article-title":"Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms","volume":"24","author":"Sahajpal","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"Del(17p) without TP53 Mutation Confers a Poor Prognosis in Intensively Treated Newly Diagnosed Patients with Multiple Myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Marcon, C., Simeon, V., Deias, P., Facchin, G., Corso, A., Derudas, D., Montefusco, V., Offidani, M., Petrucci, M.T., and Zambello, R. (2022). Experts\u2019 Consensus on the Definition and Management of High Risk Multiple Myeloma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1096852"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High Subclonal Fraction of 17p Deletion Is Associated with Poor Prognosis in Multiple Myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and Subclonal TP53 Molecular Impairment Is Associated with Prognosis and Progression in Multiple Myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (MSMART) Consensus Guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood.2020009102","article-title":"Deletion 17p: A Matter of Size and Number?","volume":"137","author":"Zweegman","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A Compendium of Myeloma-Associated Chromosomal Copy Number Abnormalities and Their Prognostic Value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but Not KRAS Significantly Reduces Myeloma Sensitivity to Single-Agent Bortezomib Therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.2005052117","article-title":"Activating KRAS, NRAS, and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma","volume":"117","author":"Shirazi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the Value of Lenalidomide Maintenance by Extended Genetic Profiling: An Analysis of 556 Patients in the Myeloma XI Trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A High-Risk, Double-Hit, Group of Newly Diagnosed Myeloma Identified by Genomic Analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1101\/gr.229102","article-title":"The Human Genome Browser at UCSC","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH Locus Breakpoints in Multiple Myeloma Indicates a Subset of Translocations Appear to Occur in Pregerminal Center B Cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC Dysregulation in the Progression of Multiple Myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/bloodadvances.2018023572","article-title":"High-Resolution Architecture and Partner Genes of MYC Rearrangements in Lymphoma with DLBCL Morphology","volume":"2","author":"Chong","year":"2018","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2022016212","article-title":"The Location of the t(4;14) Translocation Breakpoint within the NSD2 Gene Identifies a Subset of Patients with High-Risk NDMM","volume":"141","author":"Stong","year":"2023","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4687\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:56:22Z","timestamp":1760129782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":66,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15194687"],"URL":"https:\/\/doi.org\/10.3390\/cancers15194687","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]}}}